Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Century Therapeutics Inc (NQ: IPSC ) 2.500 -0.160 (-6.02%) Streaming Delayed Price Updated: 4:00 PM EDT, Jul 19, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 121,760 Open 2.670 Bid (Size) 2.490 (48) Ask (Size) 2.500 (30) Prev. Close 2.660 Today's Range 2.480 - 2.700 52wk Range 1.280 - 5.510 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News 5 Analysts Assess Century Therapeutics: What You Need To Know June 04, 2024 Via Benzinga Century Therapeutics Presents Interim Results from Phase 1 ELiPSE-1 Study at ASCO 2024 Annual Meeting June 03, 2024 From Century Therapeutics, Inc. Via GlobeNewswire Performance YTD -31.32% -31.32% 1 Month -7.06% -7.06% 3 Month -19.09% -19.09% 6 Month -34.73% -34.73% 1 Year -22.60% -22.60% More News Read More Century Therapeutics Presents Preclinical Data Highlighting Advances in iPSC Platform Technology and Programs at 2024 ASGCT Annual Meeting May 10, 2024 From Century Therapeutics, Inc. Via GlobeNewswire IPSC Stock Earnings: Century Therapeutics Beats EPS, Misses Revenue for Q1 2024 May 09, 2024 Via InvestorPlace Century Therapeutics: Q4 Earnings Insights March 14, 2024 Via Benzinga Century Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates May 09, 2024 From Century Therapeutics, Inc. Via GlobeNewswire Century Therapeutics to Present at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit April 23, 2024 From Century Therapeutics, Inc. Via GlobeNewswire Small-Cap Firm Century Therapeutics' Expands into Autoimmune Diseases, Analyst Says Clade Therapeutics Acquisition Intriguing April 11, 2024 Via Benzinga Century Therapeutics Strengthens Position in Autoimmune Disease with Strategic Pipeline Expansion Supported by $60 Million Private Placement and Acquisition of Clade Therapeutics April 11, 2024 From Century Therapeutics, Inc. Via GlobeNewswire Century Therapeutics Presents New Preclinical Data Highlighting iPSC-derived Cell Therapy Platform Technology at the 2024 American Association for Cancer Research (AACR) Annual Meeting April 08, 2024 From Century Therapeutics, Inc. Via GlobeNewswire Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors March 25, 2024 From Sagimet Biosciences Inc. Via GlobeNewswire Century Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference March 19, 2024 From Century Therapeutics, Inc. Via GlobeNewswire IPSC Stock Earnings: Century Therapeutics Misses EPS, Misses Revenue for Q4 2023 March 14, 2024 Via InvestorPlace Century Therapeutics Reports Full Year 2023 Financial Results and Provides Business Updates March 14, 2024 From Century Therapeutics, Inc. Via GlobeNewswire Century Therapeutics Announces Six Upcoming Poster Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting March 05, 2024 From Century Therapeutics, Inc. Via GlobeNewswire 3 Millionaire-Maker Under-$10 Stocks to Buy in February 2024 February 22, 2024 Via InvestorPlace Century Therapeutics to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference February 01, 2024 From Century Therapeutics, Inc. Via GlobeNewswire IN8bio's Phase 1 Clinical Trial Of INB-100 Offers Hope To Leukemia Patients With Promising Data January 22, 2024 Via Benzinga Russell 2000 Rallies To 16-Month Highs: Best Performing Small-Cap Stocks Popping Over 80% In December December 19, 2023 Via Benzinga Topics ETFs Century Therapeutics Presents Initial Data from CNTY-101 Phase 1 ELiPSE-1 Trial Supporting the Potential for a Multi-Dosing Strategy for CAR iNK Enabled by Allo-Evasion™ Edits December 09, 2023 From Century Therapeutics, Inc. Via GlobeNewswire Century Therapeutics to Host Conference Call to Discuss Preliminary Clinical Data from Phase 1 ELiPSE-1 trial of CNTY-101 in Relapsed or Refractory B-cell Lymphomas and Planned Phase 1 Study in Systemic Lupus Erythematosus December 06, 2023 From Century Therapeutics, Inc. Via GlobeNewswire Century Therapeutics Receives FDA Clearance of IND Application for CNTY-101 in Systemic Lupus Erythematosus December 06, 2023 From Century Therapeutics, Inc. Via GlobeNewswire Penny Stock Jackpots: 3 High-Stakes Picks With 10-Bagger Potential December 05, 2023 Via InvestorPlace Harnessing The Power Of Gamma-Delta T Cells In Cancer Therapy: IN8bio's Innovative Approach November 27, 2023 Via Benzinga Century Therapeutics to Present at the Piper Sandler 35th Annual Healthcare Conference November 21, 2023 From Century Therapeutics, Inc. Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
